Eli Lilly and Company $LLY Stock Sold by Cidel Asset Management Inc.

Cidel Asset Management Inc. lessened its position in Eli Lilly and Company (NYSE:LLY) by 16.2% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 16,647 shares of the company’s stock after selling 3,207 shares during the period. Cidel Asset Management Inc.’s holdings in Eli Lilly and Company were worth $19,262,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Marshall & Sterling Wealth Advisors Inc. lifted its position in Eli Lilly and Company by 60.0% in the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock valued at $37,000 after acquiring an additional 15 shares in the last quarter. AlphaCentric Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 1st quarter worth $42,000. Foresight Capital Management Advisors Inc. bought a new stake in shares of Eli Lilly and Company in the 3rd quarter worth $49,000. Caitlin John LLC bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth $64,000. Finally, IMG Wealth Management Inc. raised its stake in shares of Eli Lilly and Company by 500.0% in the second quarter. IMG Wealth Management Inc. now owns 60 shares of the company’s stock worth $72,000 after purchasing an additional 50 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
• Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
• Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
• Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,415.64 on Monday. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. The stock has a market capitalization of $1.33 trillion, a PE ratio of 45.95, a price-to-earnings-growth ratio of 1.80 and a beta of 0.40. The firm’s 50 day moving average price is $1,197.72 and its 200-day moving average price is $1,092.57. Eli Lilly and Company has a twelve month low of $834.19 and a twelve month high of $1,449.68.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The company had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. During the same period in the previous year, the business posted $7.02 earnings per share. The firm’s quarterly revenue was up 38.6% compared to the same quarter last year. Equities research analysts expect that Eli Lilly and Company will post 35.18 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s payout ratio is presently 22.46%.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald Zakrowski sold 2,000 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock worth $15,958,170 in the last three months. Corporate insiders own 0.14% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Royal Bank Of Canada upped their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company an “outperform” rating in a report on Friday. Sanford C. Bernstein reissued an “outperform” rating and issued a $1,450.00 target price on shares of Eli Lilly and Company in a research report on Monday, October 26th. TD Cowen reissued a “buy” rating and issued a $1,250.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. BMO Capital Markets restated an “outperform” rating and set a $1,650.00 target price on shares of Eli Lilly and Company in a research note on Friday. Finally, Leerink Partners raised their price target on shares of Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an “outperform” rating in a report on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $1,398.43.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.